UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 18

of 'Chronic thromboembolic pulmonary hypertension: Medical treatment'

18
TI
Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.
AU
McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S
SO
Ann Intern Med. 1999;130(9):740.
 
BACKGROUND: Treatment of patients with secondary pulmonary hypertension has been unsatisfactory.
OBJECTIVE: To describe exercise capacity, functional class, and hemodynamic variables after long-term intravenous infusion of prostacyclin in patients with secondary pulmonary hypertension.
DESIGN: Case series.
SETTING: Academic referral center.
PATIENTS: 33 patients with secondary, precapillary pulmonary hypertension (New York Heart Association class III or IV).
INTERVENTION: Continuous intravenous prostacyclin administered by portable infusion pump on a compassionate-use basis.
MEASUREMENTS: Functional class, treadmill time, and hemodynamic variables.
RESULTS: Patients were followed for an average of 12.7 +/- 5.6 months. Exercise tolerance and New York Heart Association class improved in each patient. The duration of treadmill exercise increased from 186 seconds to 491 seconds, an increase of 305 seconds (95% CI, 194 to 417 seconds; P<0.001). Mean pulmonary artery pressure decreased from 60 mm Hg to 46 mm Hg, a decrease of 14 mm Hg (CI, 9 to 19 mm Hg; P<0.001). Cardiac output increased from 3.90 L/min to 6.30 L/min, an increase of 2.40 L/min (CI, 1.56 to 3.25 L/min; P<0.001). The pulmonary vascular resistance decreased from 1143 dynes x s/cm5 to 575 dynes x s/cm5, a decrease of 567 dynes x s/cm5 (CI, 407 to 727 dynes x s/cm5; P<0.001). Patients with collagen vascular disease, congenital heart disease, and portopulmonary hypertension were analyzed with other patients and separately. All groups had a statistically significant reduction in mean pulmonary artery pressure and a statistically significant increase in cardiac output.
CONCLUSION: Intravenous prostacyclin may be effective in the treatment of patients with certain types of secondary pulmonary hypertension.
AD
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA.
PMID